I'm looking
for help...
Aidpage is free!
   

Free downloads: GrantGate®  Federal Money Retriever®

SBIR/STTR: CIRCULATING CELLS AND DNA IN CANCER DETECTION

Published on AidPage by IDILOGIC on Jun 24, 2005
Administered by:

Department of Health and Human Services, National Institutes of Health, National Institutes of Health
(see all US Federal Agencies)

Explore all postings for this grant program:
Applications Due:


February 14, 2005; June 13, 2005; October 12, 2005

total funding: Not Available
max award: $100,000
min award: none
cost sharing, matching: No
number of awards: Not Available
type of funding: Grant
Description:

The Division of Cancer Prevention of the National Cancer Institute invites
small business applications for research projects to develop novel
technologies for capturing, enriching, and preserving exfoliated abnormal
cells and circulating DNA from body fluids or effusions and to develop
methods to concentrate these cells and DNA for cancer biomarker detection.
In body fluids, such as sputum, the number of exfoliated tumor cells is often
low compared to the number of normal cells, making it difficult to detect
these abnormal cells by routine cytopathology. Separation of dysplastic
cells from degenerating cells and cells undergoing non-specific reactive
changes is problematic. Moreover, exfoliated cells are frequently
contaminated with normal cells, bacteria, and cellular debris. Therefore,
enrichment methods are needed to allow for routine detection and molecular
analysis of small numbers of exfoliated cells.
Circulating extracellular DNA was first reported in 1948. It has been shown
that the circulating DNA in the blood of cancer patients has genetic
characteristics identical to those of the primary tumors. Thus, circulating
DNA is an important material that may be useful for cancer detection.
Currently available methods for isolating undegraded circulating DNA are
limited, and there is a need to develop novel methods which improve the yield
of undegraded DNA and to adapt detection assays so that this DNA can be used
to detect mutations, microsatellite instabilities, loss of heterozygosity,
epigenetic changes, and other molecular genetic changes.
This RFA will utilize the Small Business Innovation Research (SBIR) and Small
Business Technology Transfer (STTR) mechanisms, but will be run in parallel
with a program announcement of identical scientific scope (PA-04-035) that
will utilize the exploratory/developmental (R21) grant mechanism.

Who can apply:

Anyone/General Public
City Or Township Governments
County Governments
Federally Recognized Indian Tribal Governments
Independent School Districts
Individual/Family
Minority Group
Native American Organization
Non-Government - General
Nonprofits Having A 501(C)(3) Status With The IRS, Other Than Institutions Of Higher Education
Nonprofits That Do Not Have A 501(C)(3) Status With The IRS, Other Than Institutions Of Higher Education
Other Private Institution/Organization
Private Institutions Of Higher Education
Private Nonprofit Institution/Organization (Includes Institutions Of Higher Education, Hospitals)
Profit Organization
Public And State Controlled Institutions Of Higher Education
Public Housing Authorities/Indian Housing Authorities
Small Business (Less Than 500 Employees
Special District Governments
State (Includes District Of Columbia; Includes Institutions Of Higher Education And Hospitals)
U.S. Territories And Possessions (Includes Institutions Of Higher Education, Hospitals)

Eligible functional categories:
Funding Sources:

Cancer Cause and Prevention Research
Cancer Detection and Diagnosis Research

More Information:

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-06-001.html

If you have problems accessing the full announcement, please contact: Webmaster, NIH

Address Info:

Department of Health and Human Services, National Institutes of Health, National Institutes of Health

SPONSORED LINKS
Free downloads: GrantGate®  Federal Money Retriever®
Apply for grants and loans! Click here to start